Alnylam Pharmaceuticals (ALNY) Short Interest Ratio & Short Volume $326.09 +3.26 (+1.01%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Alnylam Pharmaceuticals Short Interest DataAlnylam Pharmaceuticals (ALNY) has a short interest of 3.38 million shares, representing 2.63% of the float (the number of shares available for trading by the public). This marks a -2.03% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.4, indicating that it would take 3.4 days of the average trading volume of 859,514 shares to cover all short positions.Current Short Interest3,380,000 sharesPrevious Short Interest3,450,000 sharesChange Vs. Previous Month-2.03%Dollar Volume Sold Short$1.04 billionShort Interest Ratio3.4 Days to CoverLast Record DateJune 15, 2025Outstanding Shares130,388,000 sharesShort Percent of Float2.63%Today's Trading Volume943,507 sharesAverage Trading Volume859,514 sharesToday's Volume Vs. Average110% Short Selling Alnylam Pharmaceuticals? Sign up to receive the latest short interest report for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartALNY Short Interest Over TimeALNY Days to Cover Over TimeALNY Percentage of Float Shorted Over Time Alnylam Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20253,380,000 shares $1.04 billion -2.0%2.6%3.4 $307.99 5/31/20253,450,000 shares $1.05 billion -6.3%2.7%3.3 $304.59 5/15/20253,680,000 shares $1.04 billion +16.8%2.9%3.7 $283.40 4/30/20253,150,000 shares $829.21 million +2.9%N/A3.3 $263.24 4/15/20253,060,000 shares $706.65 million +2.3%2.4%3.4 $230.93 3/31/20252,990,000 shares $807.36 million +17.7%2.3%3.5 $270.02 3/15/20252,540,000 shares $614.07 million +2.0%2.0%3.4 $241.76 2/28/20252,490,000 shares $614.41 million -22.7%2.0%3.7 $246.75 2/15/20253,220,000 shares $825.77 million +9.5%2.5%4.8 $256.45 1/31/20252,940,000 shares $797.65 million -6.7%N/A4.2 $271.31 Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20253,150,000 shares $790.68 million -6.0%N/A4.2 $251.01 12/31/20243,350,000 shares $788.29 million -4.0%N/A4.4 $235.31 12/15/20243,490,000 shares $856.59 million +3.0%N/A4.5 $245.44 11/30/20243,390,000 shares $857.91 million -9.4%N/A4.4 $253.07 11/15/20243,740,000 shares $880.99 million +1.1%N/A4.3 $235.56 10/31/20243,700,000 shares $986.38 million -23.6%N/A4.6 $266.59 10/15/20244,840,000 shares $1.39 billion +7.3%N/A5.8 $287.36 9/30/20244,510,000 shares $1.24 billion +1.4%N/A5.5 $275.03 9/15/20244,450,000 shares $1.18 billion +18.0%N/A3.8 $265.27 8/31/20243,770,000 shares $990.34 million -16.6%N/A3.1 $262.69 8/15/20244,520,000 shares $1.19 billion +4.4%N/A4 $262.70 7/31/20244,330,000 shares $1.03 billion -3.6%N/A4 $237.46 7/15/20244,490,000 shares $1.15 billion +22.0%N/A4.5 $256.18 6/30/20243,680,000 shares $894.24 million +72.8%N/A3.9 $243.00 6/15/20242,130,000 shares $341.63 million -14.1%N/A2.6 $160.39 5/31/20242,480,000 shares $368.11 million -2.4%N/A4.4 $148.43 5/15/20242,540,000 shares $374.40 million -3.4%N/A4.3 $147.40 4/30/20242,630,000 shares $378.59 million +5.2%N/A3.2 $143.95 4/15/20242,500,000 shares $369.25 million -10.7%N/A3 $147.70 3/31/20242,800,000 shares $418.46 million +4.1%N/A3.3 $149.45 3/15/20242,690,000 shares $401.54 million -11.5%N/A3.2 $149.27 2/29/20243,040,000 shares $459.31 million -23.8%N/A3.6 $151.09 2/15/20243,990,000 shares $588.25 million -0.5%N/A5 $147.43 1/31/20244,010,000 shares $693.37 million -7.4%N/A6.5 $172.91 1/15/20244,330,000 shares $837.38 million -8.5%N/A7.4 $193.39 12/31/20234,730,000 shares $905.37 million -5.2%N/A7.6 $191.41 12/15/20234,990,000 shares $924.35 million -2.0%N/A7.8 $185.24 11/30/20235,090,000 shares $856.39 million -1.9%N/A7.6 $168.25 11/15/20235,190,000 shares $887.75 million -1.5%N/A8 $171.05 10/31/20235,270,000 shares $799.99 million -1.7%N/A8.3 $151.80The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 10/15/20235,360,000 shares $901.12 million +3.9%N/A8.7 $168.12 9/30/20235,160,000 shares $913.84 million +0.2%N/A8.6 $177.10 9/15/20235,150,000 shares $952.70 million -2.8%N/A9 $184.99 8/31/20235,300,000 shares $1.05 billion -1.5%N/A9.9 $197.82 8/15/20235,380,000 shares $969.10 million +1.7%N/A10.2 $180.13 7/31/20235,290,000 shares $1.03 billion +6.9%N/A9.7 $195.40 7/15/20234,950,000 shares $975.65 million -0.6%N/A8.4 $197.10 6/30/20234,980,000 shares $945.90 million +0.4%N/A8 $189.94 6/15/20234,960,000 shares $1.00 billion -1.8%N/A7.4 $202.34 5/31/20235,050,000 shares $934.30 million -1.4%N/A7 $185.01 5/15/20235,120,000 shares $1.06 billion +0.8%N/A6.3 $206.20 4/30/20235,080,000 shares $1.01 billion +2.2%N/A6.2 $199.20 4/15/20234,970,000 shares $1.01 billion -4.1%N/A6 $203.92 3/31/20235,180,000 shares $1.04 billion +5.1%N/A6.4 $200.32 3/15/20234,930,000 shares $915.75 million -8.5%N/A6.3 $185.75 2/28/20235,390,000 shares $1.03 billion +5.7%N/A7 $191.45 2/15/20235,100,000 shares $1.13 billion -4.3%N/A6.5 $222.10 1/31/20235,330,000 shares $1.21 billion -6.2%N/A7.1 $226.40 1/15/20235,680,000 shares $1.34 billion +11.2%N/A7.3 $235.53 12/30/20225,110,000 shares $1.21 billion -5.4%N/A6.2 $237.65 12/15/20225,400,000 shares $1.24 billion +8.2%N/A6.1 $229.37 11/30/20224,990,000 shares $1.10 billion -10.3%N/A5.1 $220.59 11/15/20225,560,000 shares $1.19 billion -7.8%N/A5.7 $214.29 10/31/20226,030,000 shares $1.25 billion +25.6%N/A6.1 $207.26 10/15/20224,800,000 shares $890.54 million +5.7%N/A4.2 $185.53 9/30/20224,540,000 shares $908.73 million +3.7%N/A4.2 $200.16 9/15/20224,380,000 shares $913.14 million +4.3%N/A4.2 $208.48 8/31/20224,200,000 shares $868.01 million -16.0%N/A4 $206.67 8/15/20225,000,000 shares $1.16 billion +1.4%N/A5.2 $231.01 7/31/20224,930,000 shares $700.26 million -1.2%N/A4.9 $142.04 7/15/20224,990,000 shares $725.50 million +4.2%N/A5.8 $145.39 6/30/20224,790,000 shares $698.62 million +1.1%N/A5.5 $145.85 6/15/20224,740,000 shares $642.03 million -15.7%5.0%5.4 $135.45 5/31/20225,620,000 shares $707.00 million -4.1%N/A6.8 $125.80 5/15/20225,860,000 shares $741.11 million -1.0%N/A6.7 $126.47 4/30/20225,920,000 shares $789.91 million +2.3%N/A7 $133.43 4/15/20225,790,000 shares $968.90 million +11.8%N/A7.1 $167.34 3/31/20225,180,000 shares $845.84 million +9.5%N/A6.4 $163.29 3/15/20224,730,000 shares $723.31 million +3.7%N/A5.4 $152.92 2/28/20224,560,000 shares $719.80 million +3.9%N/A5.2 $157.85 2/15/20224,390,000 shares $672.99 million +8.1%N/A5.3 $153.30 1/31/20224,060,000 shares $558.66 million +2.8%3.6%5.1 $137.60 1/15/20223,950,000 shares $586.58 million +11.9%N/A4.8 $148.50 12/31/20213,530,000 shares $598.62 million -6.1%N/A4.6 $169.58 12/15/20213,760,000 shares $718.39 million -4.8%N/A5.1 $191.06 11/30/20213,950,000 shares $726.01 million -2.5%N/A6.5 $183.80 11/15/20214,050,000 shares $701.91 million +4.9%N/A6.8 $173.31 10/29/20213,860,000 shares $615.90 million -0.5%N/A6.4 $159.56 10/15/20213,880,000 shares $809.21 million -3.2%N/A7.1 $208.56 9/30/20214,010,000 shares $757.13 million -9.3%N/A6.7 $188.81The $7 company helping Nvidia build the world’s first trillion-dollar robot … (Ad)Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.Now he's identified his next potential winner. Click here to find out more. 9/15/20214,420,000 shares $828.66 million -8.5%N/A7 $187.48 8/31/20214,830,000 shares $972.91 million -3.6%N/A7.2 $201.43 8/13/20215,010,000 shares $984.67 million -1.0%N/A7.3 $196.54 7/30/20215,060,000 shares $905.44 million +19.9%N/A7.7 $178.94 7/15/20214,220,000 shares $725.63 million -2.3%3.6%6.8 $171.95 6/30/20214,320,000 shares $732.33 million -6.7%3.7%7.2 $169.52 6/15/20214,630,000 shares $770.90 million +9.2%4.0%8.7 $166.50 5/28/20214,240,000 shares $602.04 million -6.2%3.7%8.6 $141.99 5/14/20214,520,000 shares $600.80 million +9.4%N/A9.1 $132.92 4/30/20214,130,000 shares $576.92 million +0.7%N/A7.7 $139.69 4/15/20214,100,000 shares $567.07 million +12.3%N/A7 $138.31 3/31/20213,650,000 shares $493.22 million -1.9%N/A5.3 $135.13 3/15/20213,720,000 shares $528.98 million +0.5%N/A5.2 $142.20 2/26/20213,700,000 shares $542.38 million +5.1%N/A5.4 $146.59 2/12/20213,520,000 shares $582.14 million -4.9%N/A5.2 $165.38 1/29/20213,700,000 shares $572.54 million -4.4%N/A5.4 $154.74 1/15/20213,870,000 shares $638.82 million +10.9%N/A5.9 $165.07 12/31/20203,490,000 shares $457.33 million -4.6%N/A6.4 $131.04 12/15/20203,660,000 shares $485.65 million -3.2%N/A7.2 $132.69 11/30/20203,780,000 shares $490.87 million +1.3%N/A7.4 $129.86 11/15/20203,730,000 shares $505.45 million +3.9%N/A7.2 $135.51 10/30/20203,590,000 shares $442.72 million +5.9%N/A7.5 $123.32 10/15/20203,390,000 shares $487.85 million +4.0%N/A7.3 $143.91 9/30/20203,260,000 shares $474.66 million -9.2%N/A6.6 $145.60 9/15/20203,590,000 shares $468.53 million -10.7%N/A6.2 $130.51 8/31/20204,020,000 shares $533.21 million -5.6%N/A6.1 $132.64 8/14/20204,260,000 shares $579.96 million No ChangeN/A6.2 $136.14 7/31/20204,260,000 shares $620.94 million -9.9%N/A5.7 $145.76 7/15/20204,730,000 shares $747.43 million -13.1%N/A5.8 $158.02 6/30/20205,440,000 shares $804.63 million -7.0%N/A6.2 $147.91 ALNY Short Interest - Frequently Asked Questions What is Alnylam Pharmaceuticals' current short interest? Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 3,380,000 shares of ALNY short. 2.63% of Alnylam Pharmaceuticals' shares are currently sold short. Learn More on Alnylam Pharmaceuticals' current short interest. What is a good short interest ratio for Alnylam Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALNY shares currently have a short interest ratio of 3.0. Learn More on Alnylam Pharmaceuticals's short interest ratio. Which institutional investors are shorting Alnylam Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Quaker Wealth Management LLC, Jane Street Group LLC, Goldman Sachs Group Inc., Parallax Volatility Advisers L.P., Millennium Management LLC, 683 Capital Management LLC, Twin Tree Management LP, Kingdon Capital Management L.L.C., PEAK6 LLC, Jane Street Group LLC, Walleye Trading LLC, Walleye Capital LLC, Garda Capital Partners LP, Altium Capital Management LLC, Persistent Asset Partners Ltd, Arrowpoint Investment Partners Singapore Pte. Ltd., Simplex Trading LLC, JPMorgan Chase & Co., Wolverine Asset Management LLC, and Portman Square Capital LLP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Alnylam Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.63% of Alnylam Pharmaceuticals' floating shares are currently sold short. Is Alnylam Pharmaceuticals' short interest increasing or decreasing? Alnylam Pharmaceuticals saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 3,380,000 shares, a drop of 2.0% from the previous total of 3,450,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Alnylam Pharmaceuticals' short interest compare to its competitors? 2.63% of Alnylam Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Alnylam Pharmaceuticals: Amgen Inc. (2.47%), Gilead Sciences, Inc. (1.85%), Vertex Pharmaceuticals Incorporated (1.57%), Regeneron Pharmaceuticals, Inc. (1.95%), Biogen Inc. (2.32%), Incyte Corporation (4.29%), United Therapeutics Corporation (3.66%), Neurocrine Biosciences, Inc. (3.71%), Exelixis, Inc. (7.73%), BioMarin Pharmaceutical Inc. (2.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Alnylam Pharmaceuticals stock? Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. ALNY shares are trading up $2.55 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Alnylam Pharmaceuticals? A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further. How often is Alnylam Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Amgen Short Interest Gilead Sciences Short Interest Vertex Pharmaceuticals Short Interest Regeneron Pharmaceuticals Short Interest Biogen Short Interest Incyte Short Interest United Therapeutics Short Interest Neurocrine Biosciences Short Interest Exelixis Short Interest BioMarin Pharmaceutical Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALNY) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts